Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial
Wilfried Eberhardt(National Center for Tumor Diseases), S. Seeber, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), J. Schütte(University of Duisburg-Essen), L. Schlenger(Charité - Universitätsmedizin Berlin), H. Wilke(Kliniken Essen-Mitte), Michael Flaßhove(University of Duisburg-Essen), S. Kolks(University of Duisburg-Essen), Georg Stüben, D Greschuchna(Ruhrlandklinik), Mark Müller, H. Sack(West German Heart and Vascular Center Essen), Georgios Stamatis(Ruhrlandklinik), Helmut Teschler(Ruhrlandklinik), Martin Stuschke(Essen University Hospital), Volker Budach(Humboldt-Universität zu Berlin)
Cited by 115
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
|New England Journal of Medicine|2015|1k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872